<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112794">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02120066</url>
  </required_header>
  <id_info>
    <org_study_id>Kyorineye015</org_study_id>
    <nct_id>NCT02120066</nct_id>
  </id_info>
  <brief_title>Submacular Hemorrhage Associated With Retinal Arterial Macro Aneurysm</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyorin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyorin University</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of surgical outcome of vitrectomy with subretinal injection of recombinant
      tissue-plasminogen activator for submacular hemorrhage associated with retinal arterial
      macroanuerysms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Displacement of sub macular hemorrhage</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anatomical recovery detected funduscopy and optical coherence tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual recovery after surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Submacular Hemorrhage</condition>
  <condition>Ruptured Retinal Arterial Macro Aneurysms</condition>
  <arm_group>
    <arm_group_label>Vitrectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy for submacular hemorrhage</intervention_name>
    <arm_group_label>Vitrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subretinal injection of tissue-plasminogen activator</intervention_name>
    <arm_group_label>Vitrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients with sub macular hemorrhage associated with ruptured retinal arterial
             macro aneurysms

        Exclusion Criteria:

          -  The eyes with preretinal or intraretinal hemorrhage at the fovea

          -  The patients with follow-up less than 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyorin Eye Center</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.eye-center.org</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyorin University</investigator_affiliation>
    <investigator_full_name>Makoto Inoue</investigator_full_name>
    <investigator_title>Associate professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Submacular hemorrhage</keyword>
  <keyword>Vitrectomy</keyword>
  <keyword>tissue- plasminogen activator</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
